9 Oct 2020 16:05
Mereo BioPharma Group plc
Director and PDMR Dealings
London and Redwood City, Calif., October 9, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on October 7 2020 Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 12,711 American Depositary Shares (ADSs) at a price of USD 2.36 per ADS, Brian Schwartz, Non-Executive Director of Mereo, purchased 20,000 ADSs at a price of USD 2.35 per ADS and John Richard, Head of Corporate Development of Mereo, purchased 6,500 ADSs at a price of USD 2.36 per ADS.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 | Details of the person discharging managerial responsibilities | |||||
a) | Name | Denise Scots-Knight | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc | ||||
b) | LEI | 213800U8JQHIJOS5AS09 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
| ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | 30043.72 | ||||
e) | Date of the transaction | 2020-10-07 | ||||
f) | Place of the transaction | XNMS | ||||
1 | Details of the person discharging managerial responsibilities | |||||
a) | Name | Brian Schwartz | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc | ||||
b) | LEI | 213800U8JQHIJOS5AS09 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
| ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | 47068.00 | ||||
e) | Date of the transaction | 2020-10-07 | ||||
f) | Place of the transaction | XNMS | ||||
1 | Details of the person discharging managerial responsibilities | |||||
a) | Name | John Richard | ||||
2 | Reason for the notification | |||||
a) | Position/status | Head of Corporate Development | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc | ||||
b) | LEI | 213800U8JQHIJOS5AS09 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
| ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | 15330.06 | ||||
e) | Date of the transaction | 2020-10-07 | ||||
f) | Place of the transaction | XNMS | ||||